Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis
Abstract Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (BC) who are hormone receptor-positiv...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-08-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11322-2 |
| _version_ | 1797452316945678336 |
|---|---|
| author | Yiyuan Liu Jinyao Wu Zeqi Ji Lingzhi Chen Juan Zou Jiehua Zheng Weixun Lin Jiehui Cai Yaokun Chen Daitian Zheng Yexi Chen Zhiyang Li |
| author_facet | Yiyuan Liu Jinyao Wu Zeqi Ji Lingzhi Chen Juan Zou Jiehua Zheng Weixun Lin Jiehui Cai Yaokun Chen Daitian Zheng Yexi Chen Zhiyang Li |
| author_sort | Yiyuan Liu |
| collection | DOAJ |
| description | Abstract Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (BC) who are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). Methods We initially identified relevant studies from previous meta-analyses and then conducted a comprehensive search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases to locate additional studies published between February 2020 and September 2021. Essential data were extracted, and a network meta-analysis was performed using R 4.1.1 software with a random-effects model. Furthermore, we assigned rankings to all available treatment combinations by calculating their cumulative probability. Results Data analysis included ten reports from nine studies. Pooled results demonstrated that each treatment combination significantly reduced the hazard risk of progression-free survival (PFS) compared to treatment with an aromatase inhibitor (AI) or fulvestrant alone. However, there were no differences observed in PFS or overall survival (OS) among the different treatment combinations. Additionally, patients receiving palbociclib plus AI and abemaciclib plus AI or fulvestrant experienced more severe adverse events (AEs), with hazard ratios (HRs) of 10.83 (95% confidence interval [CI] = 2.3 to 52.51) and 4.8 (95%CI = 1.41 to 16.21), respectively. The HR for ribociclib plus AI was 9.45 (95%CI = 2.02 to 43.61), and the HR for palbociclib plus fulvestrant was 6.33 (95%CI = 1.03 to 39.86). Based on the ranking probabilities, palbociclib plus fulvestrant had the highest probability of achieving superior PFS (37.65%), followed by abemaciclib plus fulvestrant (28.76%). For OS, ribociclib plus fulvestrant ranked first (34.11%), with abemaciclib plus fulvestrant in second place (25.75%). In terms of safety, palbociclib plus AI (53.98%) or fulvestrant (51.37%) had the highest probabilities of being associated with adverse events. Conclusions Abemaciclib plus fulvestrant or ribociclib plus AI appear to be effective and relatively safe for the treatment of HR+/HER2- metastatic or advanced BC patients. However, given the reliance on limited evidence, our findings require further validation through additional studies. |
| first_indexed | 2024-03-09T15:06:50Z |
| format | Article |
| id | doaj.art-801b5bf6496543cdbfd3a5e49679b710 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-09T15:06:50Z |
| publishDate | 2023-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-801b5bf6496543cdbfd3a5e49679b7102023-11-26T13:36:40ZengBMCBMC Cancer1471-24072023-08-0123111210.1186/s12885-023-11322-2Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysisYiyuan Liu0Jinyao Wu1Zeqi Ji2Lingzhi Chen3Juan Zou4Jiehua Zheng5Weixun Lin6Jiehui Cai7Yaokun Chen8Daitian Zheng9Yexi Chen10Zhiyang Li11Department of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeDepartment of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou, University Medical CollegeAbstract Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (BC) who are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). Methods We initially identified relevant studies from previous meta-analyses and then conducted a comprehensive search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases to locate additional studies published between February 2020 and September 2021. Essential data were extracted, and a network meta-analysis was performed using R 4.1.1 software with a random-effects model. Furthermore, we assigned rankings to all available treatment combinations by calculating their cumulative probability. Results Data analysis included ten reports from nine studies. Pooled results demonstrated that each treatment combination significantly reduced the hazard risk of progression-free survival (PFS) compared to treatment with an aromatase inhibitor (AI) or fulvestrant alone. However, there were no differences observed in PFS or overall survival (OS) among the different treatment combinations. Additionally, patients receiving palbociclib plus AI and abemaciclib plus AI or fulvestrant experienced more severe adverse events (AEs), with hazard ratios (HRs) of 10.83 (95% confidence interval [CI] = 2.3 to 52.51) and 4.8 (95%CI = 1.41 to 16.21), respectively. The HR for ribociclib plus AI was 9.45 (95%CI = 2.02 to 43.61), and the HR for palbociclib plus fulvestrant was 6.33 (95%CI = 1.03 to 39.86). Based on the ranking probabilities, palbociclib plus fulvestrant had the highest probability of achieving superior PFS (37.65%), followed by abemaciclib plus fulvestrant (28.76%). For OS, ribociclib plus fulvestrant ranked first (34.11%), with abemaciclib plus fulvestrant in second place (25.75%). In terms of safety, palbociclib plus AI (53.98%) or fulvestrant (51.37%) had the highest probabilities of being associated with adverse events. Conclusions Abemaciclib plus fulvestrant or ribociclib plus AI appear to be effective and relatively safe for the treatment of HR+/HER2- metastatic or advanced BC patients. However, given the reliance on limited evidence, our findings require further validation through additional studies.https://doi.org/10.1186/s12885-023-11322-2Breast cancerAbemaciclibRibociclibPalbociclibNetwork meta-analysis |
| spellingShingle | Yiyuan Liu Jinyao Wu Zeqi Ji Lingzhi Chen Juan Zou Jiehua Zheng Weixun Lin Jiehui Cai Yaokun Chen Daitian Zheng Yexi Chen Zhiyang Li Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis BMC Cancer Breast cancer Abemaciclib Ribociclib Palbociclib Network meta-analysis |
| title | Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis |
| title_full | Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis |
| title_fullStr | Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis |
| title_full_unstemmed | Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis |
| title_short | Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis |
| title_sort | comparative efficacy and safety of different combinations of three cdk4 6 inhibitors with endocrine therapies in hr her 2 metastatic or advanced breast cancer patients a network meta analysis |
| topic | Breast cancer Abemaciclib Ribociclib Palbociclib Network meta-analysis |
| url | https://doi.org/10.1186/s12885-023-11322-2 |
| work_keys_str_mv | AT yiyuanliu comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT jinyaowu comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT zeqiji comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT lingzhichen comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT juanzou comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT jiehuazheng comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT weixunlin comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT jiehuicai comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT yaokunchen comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT daitianzheng comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT yexichen comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis AT zhiyangli comparativeefficacyandsafetyofdifferentcombinationsofthreecdk46inhibitorswithendocrinetherapiesinhrher2metastaticoradvancedbreastcancerpatientsanetworkmetaanalysis |